Key result
Prolonged preprocedural intravenous heparin therapy (≥24 hours) improved clinical and angiographic success compared to no heparin (91% vs 81%, p=0.02) in patients undergoing PTCA for unstable angina.
Why the study?
Does prolonged preprocedural intravenous heparin therapy improve clinical and angiographic success in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty?
Cohort (n=304)
Does prolonged preprocedural intravenous heparin therapy improve clinical and angiographic success in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty?
Absolute Event Rate: 91% vs 81%
p-value: p=0.02
Prolonged preprocedural intravenous heparin administration (≥24 hours) improves procedural success and decreases the risk of abrupt vessel closure in patients with unstable angina undergoing PTCA.
No takes yet. Share an insight, caveat, or question.
May support heparin pretreatment in unstable angina PTCA; hypothesis-generating and requires randomized confirmation before practice change.
Laskey et al. (1990) conducted a cohort in unstable angina (n=304). Prolonged preprocedural intravenous heparin therapy (≥24 hours) vs. Not treated with heparin was evaluated on Clinical and angiographic success (p=0.02). Prolonged preprocedural intravenous heparin therapy (≥24 hours) improved clinical and angiographic success compared to no heparin (91% vs 81%, p=0.02) in patients undergoing PTCA for unstable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: